Viatris, Inc. (VTRS)

Over the past six months, Viatris Inc. stock has experienced fluctuations, decreasing by 3.04% over the last month but rising 6.59% compared to the previous week as of October 5, 2025. Significant events include Q1 2025 earnings release with an actual EPS of -2.550 USD and Q2 2025 earnings release with an actual EPS of 0.000 USD. An FDA warning letter and import alert for the Indore, India facility in December 2024 affected 11 actively distributed products. Viatris continued strategic divestitures, including its biosimilars portfolio, and plans to divest its OTC, Women's Healthcare, and API businesses. The company reaffirmed its commitment to returning capital to shareholders in 2025, with over $450 million returned year-to-date, and expects $500 million to $650 million in total share repurchases in 2025. Viatris is scheduled to release its Q3 2025 earnings report on November 6, 2025.

The provided information does not explicitly detail the demand seasonality for Viatris Inc.'s products and services. Some products, such as influenza vaccines, would inherently experience seasonal demand. The company's focus on a broad range of medicines suggests a relatively stable demand profile across its entire portfolio, although specific product categories may exhibit seasonal patterns.

Viatris Inc. is a global healthcare company formed in November 2020 from the merger of Mylan and Pfizer's Upjohn Business, headquartered in Canonsburg, Pennsylvania. Viatris aims to empower people worldwide to live healthier lives by providing access to a broad range of high-quality medicines. The company has over 1,400 approved molecules, including iconic brands, generic drugs, complex generics, biosimilars, and OTC products. Viatris's products address a wide array of therapeutic areas, such as cardiovascular diseases, central nervous system and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, infectious diseases, oncology, respiratory and allergy, and women's healthcare.

Viatris has a global presence, delivering medicines to patients in more than 165 countries and territories, with global centers in Pittsburgh, Shanghai, and Hyderabad. Its network includes approximately 40 to 50 manufacturing sites across six continents, including locations in Australia, Egypt, France, Germany, Greater China, Hungary, India, Ireland, South Africa, Turkey, the U.S., and Zambia. Viatris organizes its operations into four reportable segments based on markets and geography: Developed Markets, Greater China, JANZ, and Emerging Markets.

In the past year, Viatris has received recognition for its corporate performance and commitment to sustainability, including being named to TIME's World's Best Companies 2023 list and USA Today's inaugural list of America's Climate Leaders 2023. Other honors include being named to Forbes' World's Best Employers 2022 and Fortune's Change the World list. The FDA warning letter and import alert for the Indore facility in December 2024 could potentially affect the company's reputation.

Viatris Inc. has a widely distributed ownership structure, with institutional investors holding approximately 73.19% to 74.92% of the company’s stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Price T Rowe Associates Inc /md/, Davis Selected Advisers, State Street Corp, Dimensional Fund Advisors Lp, and Geode Capital Management, Llc. Individual investors and insiders hold smaller percentages of the company's stock, with insiders owning approximately 0.24%.